Revised EMA biosimilars guideline focuses on animal studies and extrapolation
This article was originally published in SRA
Executive Summary
Companies developing biosimilars in Europe should soon have a clearer idea as to when animal studies will be needed, the kind of endpoints that are acceptable, and the extent to which the indications of the reference drug can be extrapolated to the biosimilar product.